ET-01 in Subjects With Lateral Canthal Lines, LCL-210
Clinical Trial to Evaluate ET-01 in Subjects With Lateral Canthal Lines
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: PATRICK MURPHY
- Phone Number: 866-337-1868
- Email: p.murphy@crmg-usa.com
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85255
- Eirion Research Site
-
-
California
-
San Diego, California, United States, 92121
- Eirion Research Site
-
-
Florida
-
Aventura, Florida, United States, 33180
- Eirion Research Site
-
Boca Raton, Florida, United States, 33486
- Eirion Research Site
-
Miami, Florida, United States, 33137
- Eirion Research Site
-
West Palm Beach, Florida, United States, 33401
- Eirion Research Site
-
-
Illinois
-
Chicago, Illinois, United States, 60654
- Eirion Research Site
-
-
Kentucky
-
Louisville, Kentucky, United States, 40241
- Eirion Research Site
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70124
- Eirion Research Site
-
-
Maryland
-
Glenn Dale, Maryland, United States, 20769
- Eirion Research Site
-
-
Michigan
-
Clinton Township, Michigan, United States, 48038
- Eirion Research Site
-
-
Minnesota
-
New Brighton, Minnesota, United States, 55112
- Eirion Research Site
-
-
New York
-
New York, New York, United States, 10075
- Eirion Research Site
-
-
Pennsylvania
-
Exton, Pennsylvania, United States, 19341
- Eirion Research Site
-
Newtown Square, Pennsylvania, United States, 19073
- Eirion Research Site
-
-
South Carolina
-
Greenville, South Carolina, United States, 29615
- Eirion Research Site
-
-
Texas
-
Houston, Texas, United States, 77056
- Eirion Research Site
-
Plano, Texas, United States, 75093
- Eirion Research Site
-
-
Virginia
-
Norfolk, Virginia, United States, 23502
- Eirion Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- able to understand and give written informed consent
- 25 - 65 years of age
- willing to have facial pictures/videos taken per protocol
- mild or less Crow's Feet wrinkles (IGA 0-2) "at rest"
- moderate to severe Crow's Feet (IGA 3-4) "on contraction"
- ability to correctly grade a series of Crow's Feet pictures
- moderate to severe Crow's Feet (SSA 3-4) "on contraction"
- have adequate vision without the use of eyeglasses to assess facial wrinkles in a mirror (contact lenses are OK)
- willingness to refrain from the use of facial fillers, retinoids, botulinum toxins, laser treatments, or any product affecting skin remodeling or that might cause an active dermal response during the course of the study
- female subjects of childbearing potential must have a negative urine pregnancy test and be non-lactating at the Baseline visit
- female subjects of childbearing potential must utilize one of the following methods of birth control throughout the study: intra-uterine device (IUD), diaphragm, a condom, a spermicidal gel or foam, oral contraceptives (provided subject has been utilizing this method for at least 3 months prior to Baseline and has not changed the brand within this period), or patch, injectable, implantable, or vaginal ring contraceptives. Subjects may also participate if they are surgically sterilized (tubal sterilization or hysterectomy) or are in menopause.
- subjects should be in good general health as determined by the Investigator and free of any disease that may interfere with study evaluations or the Investigational Product.
Exclusion Criteria:
- history of adverse reactions to any prior botulinum toxin treatments
- history of vaccination with botulinum toxin
- history of non-response to any prior botulinum toxin treatments
- any botulinum toxin treatment anywhere in the prior 6 months
- history of participation in ET-01-LCL-210 in previous Cohorts 1 or 2 at any time in the past
- history of periocular surgery, brow lift or related procedures
- soft tissue augmentation or any procedures affecting the lateral canthal region in the prior 12 months
- dermabrasion or laser treatment in the periocular region in the last 6 months
- topical prescription-strength retinoids in the prior 3 months to the treatment area
- application of any topical prescription medication to the treatment area within 14 days prior to treatment
- subjects on clinically significant, concomitant drug therapy (See Section 5.3 below).).
- present or history of neuromuscular disease, eyelid ptosis, muscle weakness or paralysis
- present or history of "dry eye"
- hemophilia, hemorrhagic disorder, hemostatic dysfunction or other blood clotting disorders
- use of systemic aminoglycosides in the week prior to treatment application
- participation in another investigational drug trial or receiving any investigational treatment(s) within 30 days of Baseline
- alcohol or drug abuse within the past 3 years
- psychiatric disease interfering with the subject's ability to give informed consent
- refusal or inability to comply with the requirements of the protocol for any reason
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Vehicle
Vehicle, topical liniment, administered once at baseline
|
topical liniment without investigational product
Other Names:
|
|
Experimental: ET-01, Dose 1
Dose 1 of botulinum toxin, Type A, topical liniment, administered once at baseline.
250µm microneedle length
|
ET-01 topical liniment
Other Names:
|
|
Experimental: ET-01, Dose 2
Dose 2 of botulinum toxin, Type A, topical liniment, administered once at baseline.
250µm microneedle length
|
ET-01 topical liniment
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
IGA (Investigators Global Assessment)
Time Frame: Week 4
|
Investigators Global Assessment.
Crow's Feet Wrinkle Scale where severity is scored between 0-4 (0=absent; 4=severe).
|
Week 4
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
IGA (Investigators Global Assessment)
Time Frame: Week 2, 4, 8,12, and 18
|
Investigators Global Assessment.
Crow's Feet Wrinkle Scale where severity is scored between 0-4 (0=absent; 4=severe).
|
Week 2, 4, 8,12, and 18
|
|
SSA (Subject Self-Assessment)
Time Frame: Week 2, 4, 8,12, and 18
|
Subject Self-Assessment.
Crow's Feet Wrinkle Scale where severity is scored between 0-4 (0=absent; 4=severe).
|
Week 2, 4, 8,12, and 18
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ET-01-LCL-210
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.